Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06353191 · ClinicalTrials.gov registry record
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 4
- Study locations
NCT06353191: Recruiting study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Mayo Clinic.
NCT06353191 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,000 participants, below the 1,135-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (12% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06353191, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Primary Outcome
Assessed by the number of participants who participate and consent to have their specimen (blood draw) retained for future research.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (4)
Florida
- Mayo Clinic in Florida - Jacksonville
- Moffitt Cancer Center - Tampa
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2031-12-31 |
What NCT06353191 shows while recruiting
NCT06353191 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,135-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06353191 reports a single indexed study location in Florida, Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06353191 about?
NCT06353191 is a clinical study titled "Biomarkers to Predict Cancer Therapy-related Cardiotoxicity". This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
What is the current status of trial NCT06353191?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-05-03. Estimated completion is 2031-12-31.
What conditions does trial NCT06353191 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.
What interventions are being tested in trial NCT06353191?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06353191?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06353191 being conducted?
This trial has 4 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06353191's enrollment target sits among peer trials
1,000 19th of 176 higher than 158 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
RECRUITING
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI